- recruitingPHASE3
Adjuvant Tebentafusp in High Risk Ocular Melanoma
This study is testing a new medicine, tebentafusp, for people with a type of eye cancer called uveal melanoma. The aim is to see if it can stop the cancer from coming back after initial treatment, especially for those at high risk.
Belgium · France · Germany - recruitingPHASE3
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
This study is testing a new treatment called bel-sar for a type of eye cancer called choroidal melanoma, or for unclear spots in the eye that might become cancer. Doctors want to see if bel-sar is safe and works better than a dummy treatment to stop these eye problems from getting worse.
United States · Australia · Austria - active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
Italy · United Kingdom - recruitingPHASE3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This study is looking at a new medicine called darovasertib for people with a type of eye cancer called uveal melanoma. We want to see if taking darovasertib before standard treatments like radiation or surgery can help improve outcomes. It's a large study involving many hospitals.
United States · Australia · Austria - active not recruitingPHASE2
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
This study is testing a new drug, roginolisib, for advanced uveal melanoma, a type of eye cancer that has spread. It compares roginolisib to standard treatments to see if it helps patients live longer and how it affects their quality of life. It's for adults whose cancer has grown after other treatments.
Italy · Spain · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.
This study is looking at a new combination of medicines, Sitravatinib and Tislelizumab, for people with a type of eye cancer called uveal melanoma that has spread to the liver. We want to see how well this combination shrinks the cancer.
Spain - authorisedHuman Pharmacology (Phase I)- Other
Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma
This study is looking at a new treatment for a serious type of eye cancer called uveal melanoma. It uses two special drugs, nivolumab and ipilimumab, before surgery. Doctors want to see if this combination can help stop the cancer from coming back.
Denmark - active not recruiting
A Prospective Natural History Study in Uveal Melanoma
This study is creating a detailed record of uveal melanoma, a rare eye cancer. It aims to understand how the disease progresses from diagnosis to treatment, helping doctors develop better ways to treat it and improve patient care.
United States · Australia · Canada